Table 2.

HBV DNA response on antiviral therapy in the treated group.

Pts	Year Dx	Baseline HBV DNA (copies/mL)	Anti-HBV therapy	HBV DNA (-) in months on anti-HBV therapy
1	2000	3.40 × 106	LAM + TDF later	3
2	2000	6.70 × 105	LAM + TDF later	8
3	2001	1.10 × 106	LAM + TDF later	5
4	2003	8.90 × 102	LAM + ADV later	10
5	2003	5.00 × 102	LAM + TDF later	6
6	2003	7.60 × 106	LAM + TDF later	9
7	2004	5.00 × 102	LAM	3
8	2004	3.30 × 105	LAM + TDF	3
9	2005	1.10 × 104	LMM + ADV	5
10	2006	1.00 × 107	LAM + TDF	8
11	2007	1.30 × 105	TLV + TDF	3
12	2008	4.40 × 102	LAM + TDF	1
131	2008	2.40 × 108	LAM + ADV	4
14	2009	1.40 × 107	TLV + TDF	7
15	2009	1.20 × 104	TDF	6
16	2010	1.40 × 105	TDF	5

LAM, lamivudine; TDF, tenofovir disoproxil fumarate; ADV, adefovir dipivoxil; TLV, telbivudine; HCC, hepatocellular carcinoma.

¹This patient discontinued antiviral drugs 1 year after HCC ablation. One year later (off medicine for a year), he returned with recurrent tumor and HBV DNA 2E + 09 (2 × 10⁹ copies/mL). He died of HCC at 50 months after diagnosis.